The global demand for Familial Amyloid Polyneuropathy Therapeutics Market is presumed to reach the valuation of nearly USD XX MN by 2027 from USD XX MN in 2020 with a CAGR of XX% under the study period of 2021 - 2027.
Familial amyloid polyneuropathy (FAP) therapeutics includes specific treatments to treat the autosomal dominant genetic disorder caused by a systemic deposition of amyloid fibrils and characterized by progressive sensory, motor, and autonomic polyneuropathy. The primary treatment for FAP involves blocking the hepatic production of mutant and wild type transthyretin gene TTR. First-line specific treatment is liver transplantation to stop the neuropathy progression to double the survival rate. In cases of severe renal or cardiac insufficiency, a combined kidney–liver or heart–liver transplantation is proposed. In recent times transthyretin tetramer stabilizers to slow the progression of peripheral neuropathy are used. The use of nonsteroidal anti-inflammatory drugs and gene silencing has been proposed.
Rising awareness about FAP, a multi-visceral and life-threatening disease resulting in multiple disabilities, is the primary stimulant for this growth market. The development of innovative therapies and increased adoption of therapeutic drugs to treat this progressive disease affecting the peripheral and autonomic nervous system will boost the market growth. The multidisciplinary approach used in treating FAP will serve as a boon for this market's steady growth. The high survival rate in patients adopting a long-term follow-up of FAP therapeutics will boost market growth. The stringent government rules and regulations for therapeutics' approval, high cost involved in the research and development of new therapeutics will be the key barriers hampering this market.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of familial amyloid polyneuropathy therapeutics.
The report segments the anthracite market and analyses it with respect to the geography, intending to keep the marketer informed and help them identify the target demographics for the product or service.
By Drug Type
By Disease Type
By Gender Type
By Distribution Channel
- Familial Amyloid Polyneuropathy-I (FAP-I)
- Familial Amyloid Polyneuropathy-II (FAP-II)
- Familial Amyloid Polyneuropathy-III (FAP-III))
- Hospital Pharmacies
- Retail Pharmacies
This section covers regional segmentation which accentuates on current and future demand for familial amyloid polyneuropathy therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Europe Familial Amyloid Polyneuropathy Therapeutics Market By Revenue (USD MN)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the familial amyloid polyneuropathy therapeutics market include Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences, Arcturus Therapeutics Inc. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.